Valuation: Design Therapeutics, Inc.

Market Cap 668M 599M 551M 499M 933M 63.46B 950M 6.57B 2.64B 33.38B 2.51B 2.45B 105B P/E 2026 *
-7.91x
P/E 2027 * -6.55x
Enterprise Value 692M 620M 570M 517M 966M 65.72B 984M 6.8B 2.73B 34.57B 2.6B 2.54B 109B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
68.13%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Design Therapeutics, Inc.

1 day-3.44%
1 week+4.30%
1 month-15.04%
3 months-12.32%
6 months-21.47%
Current year+13.86%
1 week 10.09
Extreme 10.09
11.42
1 month 9.48
Extreme 9.475
12.94
Current year 8.23
Extreme 8.23
17.25
1 year 6.16
Extreme 6.16
17.25
3 years 1.96
Extreme 1.96
17.25
5 years 1.94
Extreme 1.94
26.3
10 years 1.94
Extreme 1.94
50.5
Manager TitleAgeSince
Chief Executive Officer 56 25/08/2023
Chief Tech/Sci/R&D Officer 60 17/04/2025
Chief Tech/Sci/R&D Officer - 01/02/2025
Director TitleAgeSince
Chairman 56 18/12/2017
Director/Board Member 71 01/07/2019
Director/Board Member 49 01/02/2020
Date Insider Type Main position Quantity % Market Cap. Importance
31/03/26 Free

Director

67,500 0.1185%
02/01/26 Free

Chief Executive Officer

750,000 1.3166%
02/01/26 Free

Director

45,000 0.0790%
Change 5-day change 1-year change 3-year change Capi.($)
-3.44%+4.30%+59.40%+423.53% 668M
-0.62%-1.87%+42.87%+64.15% 63.77B
+0.35%+3.20%+14.40%+81.76% 56.37B
+0.53%+1.96%+16.24%+103.35% 54.62B
-2.81%-4.31%+23.50%+47.83% 44.06B
-0.33%-1.93%+19.28%+98.80% 42.11B
+0.55%+2.31%+225.14%+866.21% 41B
+3.27%+47.96%+112.84%+96.58% 34.92B
+1.22%-1.44%+14.57%+46.95% 32.82B
+0.89%+20.55%-40.62%+349.24% 24.7B
Average -0.04%+7.22%+48.76%+217.84% 39.5B
Weighted average by Cap. +0.17%+5.44%+48.01%+177.09%

Financials

2026 *2027 *
Net sales - -
Net income -84.9M -76.03M -69.94M -63.37M -118M -8.06B -121M -834M -335M -4.24B -319M -312M -13.37B -115M -103M -94.97M -86.06M -161M -10.95B -164M -1.13B -455M -5.76B -433M -423M -18.16B
Net Debt 23.81M 21.33M 19.62M 17.77M 33.22M 2.26B 33.85M 234M 93.91M 1.19B 89.36M 87.46M 3.75B -295M -264M -243M -220M -412M -28.02B -419M -2.9B -1.16B -14.74B -1.11B -1.08B -46.48B
Projected Income Statement - Annual - Design Therapeutics, Inc.
Logo Design Therapeutics, Inc.
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Employees
55
Date Price Change Volume
30/10/26 $10.68 -3.44% 249,544
29/10/26 $11.06 -0.18% 276,604
28/10/26 $11.08 +4.23% 522,014
27/10/26 $10.63 +2.80% 388,875
26/10/26 $10.34 +0.98% 316,692
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Design Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
10.68USD
Average target price
21.71USD
Spread / Average Target
+103.32%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Design Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. DSGN Stock